AGYTF (Allergy Therapeutics) Current Deferred Taxes Liabilities: $0.00 Mil (As of Dec. 2025)


AGYTF Allergy Therapeutics PLC AGYTF
29 GF Score
Price $0.13
GF Value $0.03
Valuation Significantly Overvalued
! 7 Warning Signs
View Full Analysis

What is Allergy Therapeutics Current Deferred Taxes Liabilities?

Allergy Therapeutics AGYTF 29 Current Deferred Taxes Liabilities is $0.00 Mil as of Dec. 2025. GuruFocus rates AGYTF with a GF Score™ of 29/100 and a GF Value™ of $0.03 (Significantly Overvalued). The stock has 7 warning signs investors should review.

Current Deferred Taxes Liabilities represent future tax liabilities, resulting from temporary differences between book (accounting) value of assets and liabilities and their tax value, or timing differences between the recognition of gains and losses in financial statements and their recognition in a tax computation. Deferred tax liabilities generally arise where tax relief is provided in advance of an accounting expense, or income is accrued but not taxed until received.

Allergy Therapeutics's current deferred tax liabilities for the quarter that ended in Dec. 2025 was $0.00 Mil.

Allergy Therapeutics Current Deferred Taxes Liabilities Related Terms

Allergy Therapeutics Current Deferred Taxes Liabilities Historical Data

* Premium members only.

The historical data trend for Allergy Therapeutics's Current Deferred Taxes Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Allergy Therapeutics Current Deferred Taxes Liabilities Chart

Allergy Therapeutics Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Current Deferred Taxes Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.99 1.04

Allergy Therapeutics Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Current Deferred Taxes Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.99 0.00 1.04 0.00
AGYTF
29GF Score
Allergy Therapeutics PLC AGYTF
Current Deferred Taxes Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Current Deferred Taxes Liabilities of $0.00 Mil mean?
Allergy Therapeutics (AGYTF) has a Current Deferred Taxes Liabilities of $0.00 Mil as of Dec. 2025. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Allergy Therapeutics and its competitors.
Is Allergy Therapeutics' Current Deferred Taxes Liabilities too high?
Allergy Therapeutics' current Current Deferred Taxes Liabilities is $0.00 Mil. Overall, Allergy Therapeutics has a GF Score™ of 29/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Allergy Therapeutics' Current Deferred Taxes Liabilities compare to ZTS and UTHR?
Allergy Therapeutics' Current Deferred Taxes Liabilities of $0.00 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Deferred Taxes Liabilities for a Drug Manufacturers company?
A good Current Deferred Taxes Liabilities depends on the Drug Manufacturers industry context. However, Current Deferred Taxes Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Deferred Taxes Liabilities mean?
A high Current Deferred Taxes Liabilities can signal that a stock is expensive relative to its fundamentals. Current Deferred Tax Liabilities records the total amount of taxes due for the period but not yet paid. View historical data on Allergy Therapeutics and its competitors. Allergy Therapeutics's current Current Deferred Taxes Liabilities is $0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Allergy Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, Allergy Therapeutics (AGYTF) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.03, compared to a current price of $0.13 — trading 333.3% above its estimated fair value. The current Current Deferred Taxes Liabilities is $0.00 Mil. Allergy Therapeutics' overall GF Score™ is 29/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Deferred Taxes Liabilities calculated?
Current Deferred Taxes Liabilities is calculated from a company's financial statements. For Allergy Therapeutics (AGYTF), the current Current Deferred Taxes Liabilities is $0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Allergy Therapeutics (AGYTF) Overvalued in 2026?

Based on GuruFocus' analysis, Allergy Therapeutics stock appears to be overvalued. The current stock price of $0.13 is trading 333.3% above its estimated GF Value™ of $0.03. GuruFocus considers Allergy Therapeutics to be Significantly Overvalued.

Key valuation signals for AGYTF:

  • Current Deferred Taxes Liabilities: $0.00 Mil
  • GF Value™: $0.03 vs. price of $0.13 (333.3% above fair value)
  • GF Score™: 29/100 with 7 warning signs

No single metric tells the full story. See the AGYTF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Allergy Therapeutics Business Description

Other Exchanges AGY:UKHHU:Germany
Address Dominion Way, Worthing, West Sussex, GBR, BN14 8SA
Allergy Therapeutics plc is an international biotechnology group focused on the diagnosis and treatment of allergic disorders through immunotherapies that target the underlying cause of disease. Its portfolio includes Pollinex, Pollinex Quattro, Acarovac, Tyrosine S/TU, Venomil, Oralvac and other allergy immunotherapy products, supported by R&D programmes such as Grass MATA MPL and VLP Peanut. The Group operates in a single class of business, being the manufacture and sale of allergy-related medicines, and maintains centralised manufacturing and research and development capabilities in the UK. Its geographical presence covers Central Europe (Germany, Austria, Switzerland and the Netherlands), Southern Europe (Spain and Italy) and the Rest of the World (including the UK).
29GF Score

Get the complete analysis for AGYTF

Current Deferred Taxes Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.13
Price
$0.03
GF Value